Dwarfism, impaired skin development, skeletal muscle atrophy, delayed bone developement, and impeded adipogenesis in mice lacking Akt1 and Akt2

被引:688
作者
Peng, XD
Xu, PZ
Chen, ML
Hahn-Windgassen, A
Skeen, J
Jacobs, J
Sundararajan, D
Chen, WS
Crawford, SE
Coleman, KG
Hay, N [1 ]
机构
[1] Univ Illinois, Coll Med, Dept Mol Genet, Chicago, IL 60607 USA
[2] Northwestern Univ, Dept Pathol, Sch Med, Chicago, IL 60611 USA
[3] Pfizer Inc, Global Res & Dev, Groton, CT 06340 USA
关键词
mTOR; 4E-BP1; S6K; TSC2; C/EBP; FKHR/FOXO;
D O I
10.1101/gad.1089403
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
To elucidate the functions of the serine/threonine kinase Akt/PKB in vivo, we generated mice lacking both akt1 and akt2 genes. Akt1/Akt2 double-knockout (DKO) mice exhibit severe growth deficiency and die shortly after birth. These mice display impaired skin development because of a proliferation defect, severe skeletal muscle atrophy because of a marked decrease in individual muscle cell size, and impaired bone development. These defects are strikingly similar to the phenotypes of IGF-1 receptor-deficient mice and suggest that Akt may serve as the most critical downstream effector of the IGF-1 receptor during development. In addition, Akt1/Akt2 DKO mice display impeded adipogenesis. Specifically, Akt1 and Akt2 are required for the induced expression of PPARgamma, the master regulator of adipogenesis, establishing a new essential role for Akt in adipocyte differentiation. Overall, the combined deletion of Akt1 and Akt2 establishes in vivo roles for Akt in cell proliferation, growth, and differentiation. These functions of Akt were uncovered despite the observed lower level of Akt activity mediated by Akt3 in Akt1/Akt2 DKO cells, suggesting that a critical threshold level of Akt activity is required to maintain normal cell proliferation, growth, and differentiation.
引用
收藏
页码:1352 / 1365
页数:14
相关论文
共 62 条
[1]   Akt2 mRNA is highly expressed in embryonic brown fat and the AKT2 kinase is activated by insulin [J].
Altomare, DA ;
Lyons, GE ;
Mitsuuchi, Y ;
Cheng, JQ ;
Testa, JR .
ONCOGENE, 1998, 16 (18) :2407-2411
[2]  
ALTOMARE DA, 1995, ONCOGENE, V11, P1055
[3]   PPARγ is required for placental, cardiac, and adipose tissue development [J].
Barak, Y ;
Nelson, MC ;
Ong, ES ;
Jones, YZ ;
Ruiz-Lozano, P ;
Chien, KR ;
Koder, A ;
Evans, RM .
MOLECULAR CELL, 1999, 4 (04) :585-595
[4]   Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo [J].
Bodine, SC ;
Stitt, TN ;
Gonzalez, M ;
Kline, WO ;
Stover, GL ;
Bauerlein, R ;
Zlotchenko, E ;
Scrimgeour, A ;
Lawrence, JC ;
Glass, DJ ;
Yancopoulos, GD .
NATURE CELL BIOLOGY, 2001, 3 (11) :1014-1019
[5]   Ten years of protein kinase B signalling: a hard Akt to follow [J].
Brazil, DP ;
Hemmings, BA .
TRENDS IN BIOCHEMICAL SCIENCES, 2001, 26 (11) :657-664
[6]   Drosophila's insulin/P13-kinase pathway coordinates cellular metabolism with nutritional conditions [J].
Britton, JS ;
Lockwood, WK ;
Li, L ;
Cohen, SM ;
Edgar, BA .
DEVELOPMENTAL CELL, 2002, 2 (02) :239-249
[7]   A human protein kinase Bγ with regulatory phosphorylation sites in the activation loop and in the C-terminal hydrophobic domain [J].
Brodbeck, D ;
Cron, P ;
Hemmings, BA .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (14) :9133-9136
[8]   New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase AKT pathway [J].
Cantley, LC ;
Neel, BG .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (08) :4240-4245
[9]   Growth retardation and increased apoptosis in mice with homozygous disruption of the akt1 gene [J].
Chen, WS ;
Xu, PZ ;
Gottlob, K ;
Chen, ML ;
Sokol, K ;
Shiyanova, T ;
Roninson, I ;
Weng, W ;
Suzuki, R ;
Tobe, K ;
Kadowaki, T ;
Hay, N .
GENES & DEVELOPMENT, 2001, 15 (17) :2203-2208
[10]   Akt1/PKBα is required for normal growth but dispensable for maintenance of glucose homeostasis in mice [J].
Cho, H ;
Thorvaldsen, JL ;
Chu, QW ;
Feng, F ;
Birnbaum, MJ .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (42) :38349-38352